N04.7 Nephrotic syndrome with diffuse crescentic glomerulonephritis

Name of the Condition

• Nephrotic Syndrome with Diffuse Crescentic Glomerulonephritis
• ICD-10 Code: N04.7

Summary

Nephrotic syndrome with diffuse crescentic glomerulonephritis is a severe kidney disorder characterized by significant protein loss in the urine (proteinuria), low blood protein levels (hypoalbuminemia), high cholesterol (hyperlipidemia), and swelling (edema). The condition involves diffuse damage to the kidney's filtering units (glomeruli), with crescent-shaped lesions forming in the glomerular tissue, indicating rapid and extensive inflammation. This form of nephrotic syndrome is often associated with rapidly progressive glomerulonephritis, a condition marked by a rapid decline in kidney function.

Causes

The condition typically arises from autoimmune processes, such as anti-glomerular basement membrane disease (e.g., Goodpasture syndrome) or immune complex-mediated diseases (e.g., lupus nephritis, IgA nephropathy). Infections, particularly bacterial or viral infections, may trigger the immune response leading to glomerular damage. In some cases, the underlying cause remains unidentified, and the condition may occur as a primary glomerular disease.

Risk Factors

• Autoimmune disorders (e.g., lupus, vasculitis)
• Prior infections (e.g., streptococcal infections)
• Exposure to certain medications or toxins
• Genetic predisposition to glomerular diseases
• Uncontrolled hypertension or diabetes

Symptoms

• Severe swelling (edema) in the legs, ankles, or around the eyes
• Foamy or frothy urine due to excess protein
• Unexplained weight gain from fluid retention
• Fatigue and loss of appetite
• High cholesterol levels
• Reduced urine output or dark urine
• Blood in the urine (hematuria)

Diagnosis

Diagnosis involves urine tests to detect proteinuria and hematuria, blood tests to assess kidney function, protein levels, and autoimmune markers, and a kidney biopsy to confirm diffuse crescentic glomerulonephritis. Imaging studies, such as ultrasound, may be used to evaluate kidney size and structure. Additional tests, including serologic studies for autoimmune conditions, help identify underlying causes.

Treatment Options

Treatment focuses on reducing inflammation, controlling proteinuria, and managing complications. Corticosteroids and immunosuppressive agents (e.g., cyclophosphamide, rituximab) are commonly used to suppress the immune response. Blood pressure management with ACE inhibitors or ARBs helps reduce proteinuria and protect kidney function. Diuretics may be prescribed to alleviate edema, and lipid-lowering medications address hyperlipidemia. In severe cases, dialysis or kidney transplantation may be necessary.

Prognosis and Follow-Up

Prognosis depends on the underlying cause, severity of kidney damage, and response to treatment. Early intervention improves outcomes, but diffuse crescentic glomerulonephritis can progress rapidly to kidney failure. Regular monitoring of kidney function, blood pressure, and protein levels is essential. Follow-up care includes ongoing medication management and periodic biopsies to assess disease activity.

Complications

• Rapid progression to kidney failure
• Fluid overload and pulmonary edema
• Increased risk of blood clots (thromboembolism)
• Infections due to immunosuppressive therapy
• Malnutrition from protein loss
• Cardiovascular disease from hyperlipidemia and hypertension

Lifestyle & Prevention

• Maintain a low-sodium, balanced diet to reduce edema and support kidney health.
• Monitor and control blood pressure and blood sugar levels.
• Avoid nephrotoxic medications (e.g., NSAIDs) unless prescribed.
• Stay hydrated and limit alcohol intake.
• Engage in regular, moderate exercise as advised by a healthcare provider.

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden, severe swelling (especially in the legs or face)
• Foamy urine or reduced urine output
• Unexplained fatigue or shortness of breath
• Blood in the urine or dark urine
• Rapid weight gain from fluid retention

Tips for Medical Coders

When coding for N04.7, ensure documentation supports the diagnosis of nephrotic syndrome with diffuse crescentic glomerulonephritis. Include details such as biopsy findings, clinical symptoms (e.g., proteinuria, edema), and any associated conditions (e.g., autoimmune disease). Verify that the code aligns with the specific histopathological description of diffuse crescentic lesions. Document the underlying cause if known, as this may impact coding accuracy and reimbursement.